LINC00511 and cancer: Lu et al. found Hepatocyte Nuclear Factor4 (HNF4) could promote LINC00511 transcription to accelerate cancer progression; therefore, the LINC00511/EZH2/IL-24 axis is a potential therapeutic target [81].